1Dr. R. Shivasuvramaniyam M.D., 2Dr. Minakshi M.D.
1Professor& Head Department of Medical Biochemistry, Jaipur National University Jaipur Rajasthan India 302017
2Associate Professor, Magathama Gandhi Medical College Jaipur, Rajasthan
DOI : https://doi.org/10.47191/ijmra/v5-i2-23Google Scholar Download Pdf
ABSTRACT:
The pandemic outbreak of noval corona virus disease (covid19) was initially noticed in a seafood market in wuhan city in china in mid-December, 2019, has spreaded to 215 countries worldwide. 2020 january7th and was temporally named 2019 n- co.v
Corona virus belongs to a large family of virus that causes illness ranging from the common cold to more severe disease, A noval corona virus is a new strain that has not been previously identified in humans on January 30th 2020 declared the noval corona virus outbreak of public health emergency of international concern (PHEIC). At that time there was 98 cases and no death in 18 countries outside china.
The official name covid-19 and SARS –COV2 was issued by the WHO on 11th February 2020 Viruses are named based on their genetic structure to facilitate the development of diagnostic test, Vaccine and medium. Virologist and the wider scientific committee do this work, so virus is are named by the international committee on taxonomy of viruses.
A recent review of the survival of human corona virus on surface found large variability ranging from 2 hours to 9 days. The survival time depends on number of factors, including the type of surface, temperature, relative humidity and specific strain of viruses.
March 11th 2020, the rapid increase in the number of cases outside china. 118000 cases had been reported in 114 countries and 4291 deaths had been reported.
Middle of the March 2020 corona out break could be characterized by “Pandemic” reporting over 40108 globally confirmed cases. As of 28th April 2020, 63% of global mortality from the virus.
The impact of the dieses on the world has been staggering both from public health and economic perspective. We evaluated whether prior or active corona virus infection influenced hematological, Biochemical and Clinical parameters of the such patients. But active corona fever resulted in higher hospitalization rate. Our data support the nation that SARS- COV-2 and co morbidity weather affects an important percentage of covid 19 pateints and leads to worse parameters, requiring greater attention from health authorities.
KEYWORDS:Covid, SARS-CO-2 Infection, SARS –CO-2 Infection with Comorbidities, hematological, Biochemical, Markers, ARDS, acute respiratory distress syndrome; SARS-CO2, corona virus disease CRP- C reactive protein; ICU, intensive care unit; PCT, procalcitonin.
REFERENCES
1) Li, X. Guan, P. Wu, et al.Early transmission dynamics in wuhan, China, of novel corona virus –infected pneumonia new England journal of medicine, 382 (2020). pp. 1199-207, 10.1056/NEJMoa2001316
2) L. Sheng, X. Wang, N. Tang, et al. clinical characteristics of moderate and severe cases with COVID-19 in Wuhan, China: a retrospective study clinical and Experimental medicine (2020), 10. 1007/s10238-020-00662-z
3) R. Kumar, V. Singh, A. Mohanty, Y. Bahurupi, P.K. Gupta Corona health -care warriors in india: Knowledge, attitude, and practices during COVID-19 outbreak J Educ health promot, 10 (44) (2021), pp. 1-8, 10.4103/jehp.jehp_524_20
4) D. Wang, B. hu, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel corona virus- infected pneumonia in wuhan, China JAMA, 323 (2020), pp. 1061—1069, 10.1001/jama.2020.1585
5) J. -F. Gautier, Y. Ravussin A new symptom of COVID -19: loss of taste and smell obesity (2020), p. 848
6) World Health organization world health organization statement on the second meeting of the international health regulations (2005) Emergency committee regarding the outbreak of novel Corona virus (2019-nCoV) (2020)
7) J. Lu, S. Hu, R. Fan, et al. ACP risk grade: a simple mortality index for patients with confirmed or suspected severe acute respiratory syndrome corona virus -2 disease (COVID -19) During the early stage of outbreak in wuhan medRxiv China (2020) p. 2020.02.20.20025510.
8) J. Liu, Y. Liu, P. Xiang, et al. Neutrophil –to- Lymphocyte ratio predicts severe illness patients with 2019 medRxiv Novel Corona virus in the Early Stage (2020) P.
9) D. Wang, R. Li, J. Wang, et al. Correlation analysis between disease Severity and Clinical and biochemical characteristics of 143 cases of COVID -19 in Wuhan, China: A descriptive study BMC infectious Disease, 20 (2020), p. 519,
10) S. Tian, H. Liu, M. Liao, et al. Analysis of mortality in patients with COVID -19: Clinical and laboratory Parameters Open Forum infectious Disease (2020), p. 7,
11) K. Wang, Z. Qiu, J. Liu, et al. Analysis of the clinical characteristics of 77 COVID -19 deaths. Scientific Reports, 10 (2020), p. 16384,
12) P. R. Martins –Filho, C.S.S. Tavares, V.S. Santos. Factors associated with mortality in patients with COVID -19. A quantitative evidence synthesis of clinical and laboratory data. European journal of internal medicine, 76 (2020), pp. 97-99.
13) Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcito patients with COVID-19. J Clin Virol 2020; 104370. [PMC free article] [PubMed] [Google Scho
14) Li H, Xiang X, Ren H, et al. Serum amyloid A is a biomarker of severe coronavirus disease i poor prognosis. J Infect 2020; 80: 646-655. [PMC free article] [PubMed] [Google Scholar]
15) Creamer AW, Kent AE, Albur M. Procalcitonin in respiratory disease: use as a biomarker for diagnosis and guiding antibiotic therapy. Breathe 2019; 15: 296-304. [PMC free article] [PubM [Google Scholar]
16) Kamat IS, Ramachandran V. Eswaran H, et al. Procalcitonin to distinguish viral from bacteri pneumonia: a systematic review and meta-analysis. Clin Infect Dis 2020; 70: 538-542. [PubMex [Google Scholar]
17) Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mort acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis 2018; 18: 95-107. [PubMed] [Google Scholar]
18) Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibi decisions: past, present and future. BMC Med 2011; 9: 107. [PMC free article] [PubMed] [Google Scholar]
19) Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID meta-analysis. Clin Chim Acta 2020; 505: 190-191. [PMC free article] [PubMed] [Google Scholar]
20) Levi M, van der Poll T. Coagulation and sepsis. Thromb Res 2017; 149: 38-44. [PubMed] [Google Scholar]
21) Lin L, Lu L, Cao W, et al. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-Review of immune changes in patients with viral pneumonia. Emerg Microbes Infect 2020; 1-14 [PMC free article] [PubMed] [Google Scholar]
22) Lue W, Yu H, Gou J, et al. Clinical pathology of critical patient with novel coronavirus pneu (COVID-19). Preprints 2020; 1-18. [Google Scholar]
23) Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost 2020; 1023-1026. [PubMed] [Google Scholar]
24) Karakike E, Giamarellos-Bourboulis EJ. Macrophage activation-like syndrome: a distinct en leading to early death in sepsis. Front Immunol 2019, 10: 55. [PMC free article] [PubMed] [Google Scholar]
25) Ramos-Casals M, Brito-Zerón P, López-Guillermo A, et al. Adult haemophagocytic syndrom Lancet 2014; 383: 1503-1516. [PubMed] [Google Scholar]
26) Veronese N, Demurtas J, Yang L, et al. Use of corticosteroids in coronavirus disease 2019 pneumonia: a systematic review of the literature. Front Med 2020; 7: 1-6. [PMC free article] [PubMed] [Google Scholar]
27) Pranata R, Lim MA, Huang 1, et al. Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: a systematic review, meta-analysis and meta-regre Renin Angiotensin Aldosterone Syst 2020; 1-11. [PMC free article] [PubMed] [Google Scholar]
28) Pranata R, Soeroto AY, Huang I, et al. Effect of chronic obstructive pulmonary disease and smoking on the outcome of COVID-19. Int J Tuberc Lung Dis. Epub ahead of print 28 may 2020 10.5588/ijtld.20.0278. [CrossRef] [Google Scholar]
Volume 05 Issue 02 February 2022
Our Services and Policies
Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected.
The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.
International Journal of Multidisciplinary Research and Analysis will publish 12 monthly online issues per year,IJMRA publishes articles as soon as the final copy-edited version is approved. IJMRA publishes articles and review papers of all subjects area.
Open access is a mechanism by which research outputs are distributed online, Hybrid open access journals, contain a mixture of open access articles and closed access articles.
International Journal of Multidisciplinary Research and Analysis initiate a call for research paper for Volume 07 Issue 05 (May 2024).
PUBLICATION DATES:
1) Last Date of Submission : 26 May 2024 .
2) Article published within a week.
3) Submit Article : editor@ijmra.in or Online
Why with us
1 : IJMRA only accepts original and high quality research and technical papers.
2 : Paper will publish immediately in current issue after registration.
3 : Authors can download their full papers at any time with digital certificate.
The Editors reserve the right to reject papers without sending them out for review.
Authors should prepare their manuscripts according to the instructions given in the authors' guidelines. Manuscripts which do not conform to the format and style of the Journal may be returned to the authors for revision or rejected. The Journal reserves the right to make any further formal changes and language corrections necessary in a manuscript accepted for publication so that it conforms to the formatting requirements of the Journal.